FDA's 2026 TEMPO Pilot: The Bridge to Reimbursement for Digital Health?

This episode delves into the U.S. FDA's upcoming Total Product Life Cycle (TPLC) Advisory Program, known as TEMPO, set to launch in 2026. We explore its potential to revolutionize the pathway for digital health and chronic-care medical devices by integrating payers early in the regulatory process. We analyze whether TEMPO can successfully bridge the gap between regulatory approval and reimbursement, or if manufacturers will still face significant hurdles in proving value to secure market access. - What is the FDA's TEMPO pilot program launching in 2026? - How does TEMPO aim to connect regulatory approval with payer reimbursement? - Why do many approved digital health devices struggle to get paid for by insurers? - What specific challenges does the program target for chronic-care device makers? - Could TEMPO reduce the time and cost of bringing new MedTech to market? - What are the potential limitations or reasons for skepticism about the pilot's success? - How can manufacturers prepare their evidence strategy for both the FDA and payers? Navigating the complex path from regulatory approval to reimbursement requires a robust strategy. Pure Global offers end-to-end consulting for MedTech and IVD companies, developing efficient pathways for approval that consider payer requirements from the start. We use advanced AI to compile and manage technical dossiers and provide continuous regulatory monitoring to keep you ahead of changes like the TEMPO pilot. Whether you're a startup or a multinational, we help you identify the best markets and build the evidence needed for successful global access. Contact Pure Global at [e-mail], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.